Drug General Information
Drug ID
D0S0WN
Former ID
DCL000070
Drug Name
Biomed 101
Drug Type
Small molecular drug
Indication Renal cancer [ICD9: 140-229, 189; ICD10:C64] Discontinued in Phase 1 [521466]
Therapeutic Class
Anticancer Agents
Company
Intarcia Therape.
Structure
Download
2D MOL

3D MOL

Formula
C28H36O7
Canonical SMILES
CCCC1=C(C=CC2=C1OC(CC2)C(=O)O)OCCCOC3=C(C(=C(C=C3)C(=O)<br />C)OC)CCC
InChI
1S/C28H36O7/c1-5-8-21-23(13-10-19-11-14-25(28(30)31)35-26(19)21)33-16-7-17-34-24-15-12-20(18(3)29)27(32-4)22(24)9-6-2/h10,12-13,15,25H,5-9,11,14,16-17H2,1-4H3,(H,30,31)
InChIKey
ZVVCSBSDFGYRCB-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Leukotriene B4 receptor 1 Target Info Binder [550277]
KEGG Pathway Neuroactive ligand-receptor interaction
NetPath Pathway IL4 Signaling Pathway
Reactome Leukotriene receptors
G alpha (q) signalling events
WikiPathways Nucleotide GPCRs
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Spinal Cord Injury
GPCR ligand binding
GPCR downstream signaling
References
Ref 521466ClinicalTrials.gov (NCT00004890) Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer. U.S. National Institutes of Health.
Ref 550277Biomed 101, a leukotriene B4 inhibitor, may decrease IL-2 toxicity. 2003 ASCO Annual Meeting. 2003.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.